检索范围:
排序: 展示方式:
null
《医学前沿(英文)》 2013年 第7卷 第1期 页码 138-142 doi: 10.1007/s11684-013-0247-5
It has been demonstrated that single nucleotide polymorphisms (SNPs) of SIPA1 (signal-induced proliferation associated gene 1) are associated with metastatic efficiency in both human and rodents. The purpose of this study was to determine whether SIPA1 545 C>T polymorphism was associated with overall survival in patients with metastatic breast cancer. In this study, SIPA1 545 C>T polymorphism was detected in 185 metastatic breast cancer patients using polymerase chain reaction-restriction fragment length polymorphism assay (PCR-RFLP). Survival curves for patients with SIPA1 545 C>T polymorphism was compared using the Kaplan-Meier method with log-rank tests. We found that SIPA1 545 C>T polymorphism was significantly associated with survival in 185 patients with metastatic breast cancer. Patients with SIPA1545 T/T genotype had a significantly worse overall survival (OS) than did patients with C/T or C/C genotype (50.0% vs. 62.9%, P = 0.042). Moreover, in multivariate analysis, as compared with the C/C or C/T genotype, the T/T genotype remained an independent unfavorable prognostic marker of OS in this cohort (hazard ratio [HR] = 2.16; 95% CI= 1.12–4.15; P = 0.022). Our findings indicate that metastatic breast cancer patients with SIPA1 545 T/T genotype have a poorer survival compared to patients with C/C or C/T genotype.
《医学前沿(英文)》 2021年 第15卷 第6期 页码 942-942 doi: 10.1007/s11684-021-0876-z
null
《医学前沿(英文)》 2016年 第10卷 第1期 页码 41-51 doi: 10.1007/s11684-016-0429-z
Midline2 (MID2) is an ubiquitin-conjugating E2 enzyme linked to tumor progression and a novel interacting partner of breast cancer 1, early-onset (BRCA1). However, the role of MID2 in breast cancer remains unknown. This study investigated the expression, prognostic value, and role of MID2 in breast cancer. The expression of MID2 mRNA and protein was significantly upregulated in breast cancer tissue and established cell lines compared with that in normal breast epithelial cells and paired adjacent non-tumor tissue (P<0.001). Immunohistochemical analysis demonstrated that MID2 was overexpressed in 272 of 284 (95.8%) paraffin-embedded, archived breast cancer tissue. Moreover, MID2 expression increased with advanced clinical stage (P<0.001). High MID2 expression was significantly associated with advanced clinical stages and T, N, and M staging (all P<0.05). Univariate and multivariate analyses indicated that high MID2 expression was an independent prognostic factor for poor overall survival in the entire cohort (93.73 vs. 172.1 months; P<0.001, log-rank test) and in subgroups with stages Tis+ I+ II and III+ IV. Furthermore, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide colony formation, and anchorage-independent growth ability assays were conducted. Results showed that siRNA silencing of MID2 expression significantly reduced MCF-7 and MDA-MB-231 cell proliferation in vitro and blocked the growth of MDA-MB-231 cell xenograft tumors in vivo (P<0.05). This study indicated that MID2 may be a novel prognostic marker and interventional target in breast cancer.
关键词: breast cancer MID2 proliferation overall survival xenograft
Qiong DAI MD, Bei LIU MD, Yukai DU MM,
《医学前沿(英文)》 2009年 第3卷 第4期 页码 452-458 doi: 10.1007/s11684-009-0080-z
关键词: meta-analysis breast cancer risk factors reproductive factors oral contraceptive use
Metabolism and immunity in breast cancer
Deyu Zhang, Xiaojie Xu, Qinong Ye
《医学前沿(英文)》 2021年 第15卷 第2期 页码 178-207 doi: 10.1007/s11684-020-0793-6
A comprehensive information database (CID) of breast cancer patients in China
null
《医学前沿(英文)》 2012年 第6卷 第2期 页码 212-216 doi: 10.1007/s11684-012-0185-7
Jacqueline CONCHA, Caroline WEINSTEIN, María Elvira Zú?IGA
《化学科学与工程前沿(英文)》 2013年 第7卷 第4期 页码 482-489 doi: 10.1007/s11705-013-1342-5
关键词: pectic extracts antiproliferative activity breast cancer enzymatic treatment
null
《医学前沿(英文)》 2016年 第10卷 第1期 页码 33-40 doi: 10.1007/s11684-016-0431-5
Breast cancer is the most common malignant tumor in women, and the incidence of this disease has increased in recent years because of changes in diet, living environment, gestational age, and other unknown factors. Previous studies focused on cancer cells, but an increasing number of recent studies have analyzed the contribution of cancer microenvironment to the initiation and progression of breast cancer. Cancer-associated fibroblasts (CAFs), the most abundant cells in tumor stroma, secrete various active biomolecules, including extracellular matrix components, growth factors, cytokines, proteases, and hormones. CAFs not only facilitate the initiation, growth, angiogenesis, invasion, and metastasis of cancer but also serve as biomarkers in the clinical diagnosis, therapy, and prognosis of breast cancer. In this article, we reviewed the literature and summarized the research findings on CAFs in breast cancer.
关键词: cancer-associated fibroblast breast cancer progression prognosis
《医学前沿(英文)》 doi: 10.1007/s11684-023-1016-8
关键词: p53 mutation triple-negative breast cancer decitabine DNMT1 IRF7 innate immune response
Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo, Binghe Xu
《医学前沿(英文)》 2021年 第15卷 第1期 页码 1-10 doi: 10.1007/s11684-020-0741-5
关键词: triple-negative breast cancer immunotherapy targeted therapy
Soy food consumption in relation to breast cancer modified by menopause status
YANG Rong, ZHANG Bin, YANG Shaoping, ZHANG Dan, DU Yukai
《医学前沿(英文)》 2008年 第2卷 第4期 页码 348-351 doi: 10.1007/s11684-008-0066-2
Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes
《医学前沿(英文)》 2023年 第17卷 第2期 页码 231-239 doi: 10.1007/s11684-022-0939-9
关键词: neoadjuvant radiotherapy oligometastatic prostate cancer radical prostatectomy
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
《医学前沿(英文)》 2010年 第4卷 第3期 页码 290-293 doi: 10.1007/s11684-010-0093-7
关键词: breast cancer postmenopausal hormone therapy unopposed estrogen therapy combined estrogen-progestin therapy
Andrew Best,Katherine James,Gerald Hysenaj,Alison Tyson-Capper,David J. Elliott
《化学科学与工程前沿(英文)》 2016年 第10卷 第2期 页码 186-195 doi: 10.1007/s11705-015-1540-4
关键词: RNA splicing gene expression breast cancer DNA damage CHK1
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen
《医学前沿(英文)》 2019年 第13卷 第1期 页码 57-68 doi: 10.1007/s11684-019-0683-y
Lung cancer is the most common incident cancer and the leading cause of cancer death. In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-T) cell has shown a promising future. Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation expressed in various types of tumors and has been detected in non-small cell lung cancer with a mutation rate of 10%. Thus, EGFRvIII is a potential antigen for targeted lung cancer therapy. In this study, CAR vectors were constructed and transfected into virus-packaging cells. Then, activated T cells were infected with retrovirus harvested from stable virus-producing single clone cell lines. CAR expression on the surfaces of the T cells was detected by flow cytometry and Western blot. The function of CAR-T targeting EGFRvIII was then evaluated. The EGFRvIII-CAR vector was successfully constructed and confirmed by DNA sequencing. A stable virus-producing cell line was produced from a single clone by limited dilution. The culture conditions for the cell line, including cell density, temperature, and culture medium were optimized. After infection with retrovirus, CAR was expressed on more than 90% of the T cells. The proliferation of CAR-T cells were induced by cytokine and specific antigen in vitro. More importantly, EGFRvIII-CART specifically and efficiently recognized and killed A549-EGFRvIII cells with an effector/target ratio of 10:1 by expressing and releasing cytokines, including perforin, granzyme B, IFN-g, and TNF-α. The in vivo study indicated that the metastasis of A549-EGFRvIII cells in mice were inhibited by EGFRvIII-CART cells, and the survival of the mice was significantly prolonged with no serious side effects. EGFRvIII-CART showed significantly efficient antitumor activity against lung cancer cells expressing EGFRvIII in vivo and in vitro. Therefore, CAR-T targeting EGFRvIII is a potential therapeutic strategy in preventing recurrence and metastasis of lung cancer after surgery.
关键词: chimeric antigen receptor T cells epidermal growth factor receptor lung cancer immunotherapy tumor immunology
标题 作者 时间 类型 操作
Association of SIPA1 545 C>T polymorphism with survival in Chinese women with metastatic breast cancer
null
期刊论文
Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer
期刊论文
Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer
null
期刊论文
Meta-analysis of the risk factors of breast cancer concerning reproductive factors and oral contraceptive
Qiong DAI MD, Bei LIU MD, Yukai DU MM,
期刊论文
Production of pectic extracts from sugar beet pulp with antiproliferative activity on a breast cancer
Jacqueline CONCHA, Caroline WEINSTEIN, María Elvira Zú?IGA
期刊论文
Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications
null
期刊论文
Decitabine induces -mediated immune responses in p53-mutated triple-negative breast cancer: a clinical
期刊论文
Soy food consumption in relation to breast cancer modified by menopause status
YANG Rong, ZHANG Bin, YANG Shaoping, ZHANG Dan, DU Yukai
期刊论文
Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes
期刊论文
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
期刊论文
Transformer2 proteins protect breast cancer cells from accumulating replication stress by ensuring productive
Andrew Best,Katherine James,Gerald Hysenaj,Alison Tyson-Capper,David J. Elliott
期刊论文